[Progress in the management of cytomegalovirus(CMV) infection].
We described the clinical feature of cytomegalovirus(CMV) infection, its epidemiology, and prognosis of congenital CMV infection. Then, the anti-viral treatment with the ganciclovir against the congenital CMV infection was discussed. We showed that the presence of CMV-DNA in the plasma was useful to determine the indication of the therapy. We also showed our case of chronic active Epstein-Barr virus infection to introduce the adoptive immune therapy as a new strategy for the treatment of severe virus infections. Lastly, application of this therapy for the CMV infection in overseas and its future prospect were described.
Tanaka
N
N
Department of Pediatrics, Nagoya University School of Medicine.
Kimura
H
H
Morishima
T
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000151:congenital / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D016219:Immunotherapy, Adoptive; D007231:Infant, Newborn; D011247:Pregnancy; D005719:gamma-Globulins / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D005719:gamma-Globulins; D015774:Ganciclovir